Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines

Cancer immunology research

Volumn 2, Issue 11, 2014, Pages 1090-1102

  Farsaci, Benedetto ^a   Donahue, Renee N ^a   Coplin, Michael A ^a   Grenga, Italia ^a   Lepone, Lauren M ^a   Molinolo, Alfredo A ^a   Hodge, James W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; CANCER VACCINE; CARBANILAMIDE DERIVATIVE; INDOLE DERIVATIVE; NICOTINAMIDE; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRROLE DERIVATIVE; RECOMBINANT VACCINE; SORAFENIB; SUNITINIB;

ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; DRUG EFFECTS; FEMALE; FLOW CYTOMETRY; HUMAN; MOUSE; MULTIMODALITY CANCER THERAPY; NEOPLASMS, EXPERIMENTAL; TRANSGENIC MOUSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CANCER VACCINES; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; FLOW CYTOMETRY; HUMANS; INDOLES; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOPLASMS, EXPERIMENTAL; NIACINAMIDE; PHENYLUREA COMPOUNDS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRROLES; VACCINES, SYNTHETIC;

EID: 84991455944     PISSN: None     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-14-0076     Document Type: Article

References (0)